Proteostasis Therapeutics (NASDAQ: PTI) dosed the first patient in a 28-day Phase 2 trial evaluating combinations of PTI-801, PTI-808 and PTI-428 for the treatment of cystic fibrosis (CF). CF is caused by a mutation in...
The FDA granted fast track and qualified infectious disease product (QIDP) designations to Matinas BioPharma’s (NYSE AMER:MTNB) MAT2203 for the treatment of cryptococcal meningitis. MAT2203 is a lipid nano-crystal...
Abeona Therapeutics (NASDAQ:ABEO) reported positive data from its ongoing Phase 1/2 clinical trial of ABO-102 for the treatment of Sanfilippo syndrome type A (MPS IIIA). Primarily affecting the central nervous system...
The German Federal Institute for Drugs and Medical Devices (BfArM) granted XPhyto Therapeutics’ German subsidiary, Bunker Pflanzenextrakte, a cannabis cultivation and extraction license for scientific purposes. Subject...
DelMar Pharmaceuticals (NASDAQ:DMPI) treated the first MGMT-unmethylated glioblastoma multiforme (GBM) patient in the adjuvant trial arm of its Phase 2 study of VAL-083. This study arm will enroll up to 24 newly...
Myovant Sciences (NASDAQ:MYOV) reported that the second of two Phase 3 studies of relugolix met its primary efficacy endpoint and six key secondary endpoints in women with uterine fibroids. Relugolix is a once daily...
Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) signed an agreement with a trial management organization (TMO) to provide four-to-six U.S.-based urology study sites that will be able to commence enrolling and treating...
Dawson James initiated coverage of Anavex Life Sciences (NASDAQ:AVXL) with a “buy” rating and $16 price target. The stock closed $2.54 on July 23. Anavex is pioneering a new treatment in CNS diseases like...
Zenabis Global (TSX:ZENA) reported that its cultivation output in June 2019 was 756 kg of dried cannabis, which represents a 40.8% outperformance relative to design capacity, or a performance ratio of 40.8%. June 2019...
Chiasma (NASDAQ:CHMA) reported positive top-line Phase 3 data from a pivotal trial evaluating its octreotide candidate, conditionally trade-named Mycapssa, for the treatment of acromegaly. Acromegaly is caused by the...